Big pharma may have genomic tool vendors to thank in part for a recent surge in R&D productivity — and it could return the favor with greater technology investment.

After declining more than 20 percent from the mid-1990s to the early-2000s, the rate at which new candidates at the 10 biggest drug makers entered clinical testing has increased 52 percent in recent years, according to a report released last week from the Tufts Center for the Study of Drug Development.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.